

AMENDMENTS

Please cancel claims 1-15 without prejudice to the Applicants' right to pursue claims of the same or similar scope in a duly-filed continuing application.

Please enter new claims 16-25 as set out below.

--16. A method for inhibiting viral replication in cells susceptible to viral infection comprising contacting said cells with a leflunomide product in an amount effective to inhibit viral virion assembly.

17. The method of claim 16 wherein the leflunomide product is N-(4-trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide (HWA 486).

18. The method of claim 16 wherein the leflunomide product is N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide (A771726).

19. The method of claim 16 wherein the virus is a herpesvirus.

20. The method of claim 16 wherein the virus is selected from the group consisting of paramyxoviruses, picornaviruses and hepatitis viruses.

21. The method of claim 16 wherein the virus is selected from the group consisting of CMV, HSV, measles virus, rhinoviruses, hepatitis B and hepatitis C.

22. The method of claim 16 further comprising contacting the cells with another anti-viral agent.

23. The method of claim 16 further comprising contacting the cells with a pyrimidine.